{"id":29155,"date":"2026-09-21T10:51:00","date_gmt":"2026-09-21T17:51:00","guid":{"rendered":"https:\/\/getheally.com\/patients\/news\/what-is-oral-semaglutide-copy"},"modified":"2026-09-22T04:27:16","modified_gmt":"2026-09-22T11:27:16","slug":"compounded-semaglutide","status":"publish","type":"post","link":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide","title":{"rendered":"Compounded semaglutide in 2026: what&#8217;s actually still legal"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Compounded semaglutide is not the workaround it was in 2023 and 2024. The FDA shortage that made mass compounding legal ended in February 2025, and by September 2026 the agency has spent a year and a half systematically closing the pathways that let telehealth shops sell it at subscription scale. As of this month, large-batch 503B compounding of semaglutide is effectively over, the FDA has proposed permanently barring it, and even patient-specific 503A compounding now requires a real, individually documented medical reason \u2014 not a boilerplate note or a B12 add-on.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">That doesn&#8217;t mean compounded semaglutide vanished overnight. It means the legal room to use it has narrowed to a specific, well-defined space, and most of what filled that space in 2023\u20132024 no longer qualifies. Here&#8217;s exactly where things stand.<\/span><\/p>\n<h2 id=\"key-takeaways\"><span style=\"font-weight: 400;\">Key takeaways<\/span><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The FDA resolved the <\/span><b>semaglutide shortage in February 2025<\/b><span style=\"font-weight: 400;\">, ending the exception that let compounding pharmacies mass-produce it.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>503A enforcement discretion ended April 22, 2025<\/b><span style=\"font-weight: 400;\">; the <\/span><b>503B window closed May 22, 2025<\/b><span style=\"font-weight: 400;\">. After those dates, ordinary compounding restrictions apply.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">On <\/span><b>April 1, 2026<\/b><span style=\"font-weight: 400;\">, the FDA reiterated that compounded semaglutide is only exempt from &#8220;essentially a copy&#8221; restrictions when a prescriber documents a <\/span><b>genuine, patient-specific clinical reason<\/b><span style=\"font-weight: 400;\"> \u2014 generic justifications don&#8217;t qualify.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The FDA explicitly named <\/span><b>semaglutide-plus-B12<\/b><span style=\"font-weight: 400;\"> as still &#8220;essentially a copy&#8221; \u2014 the most common telehealth workaround no longer holds up.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">On <\/span><b>April 30, 2026<\/b><span style=\"font-weight: 400;\">, the FDA proposed removing semaglutide (and tirzepatide, liraglutide) from the <\/span><b>503B bulks list entirely<\/b><span style=\"font-weight: 400;\">, which would close large-scale compounding for good. Public comment closed June 29, 2026; a final decision is pending.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A narrow safe harbor remains: 503A pharmacies filling <\/span><b>four or fewer prescriptions per month<\/b><span style=\"font-weight: 400;\"> of an essentially-a-copy formulation are unlikely to face enforcement \u2014 but this is discretion, not a legal green light for routine use.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The FDA has logged <\/span><b>455+ adverse event reports<\/b><span style=\"font-weight: 400;\"> tied to compounded semaglutide and <\/span><b>320+ for compounded tirzepatide<\/b><span style=\"font-weight: 400;\">, several requiring hospitalization from dosing errors.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/getheally.com\/patients\/wegovy\"><b>Wegovy<\/b><\/a><span style=\"font-weight: 400;\"> self-pay, the <\/span><a href=\"https:\/\/getheally.com\/patients\/wegovy-pills\"><b>Wegovy pill<\/b><\/a><span style=\"font-weight: 400;\">, and manufacturer savings programs have become the practical, lower-risk alternatives for patients priced out of brand-name treatment.<\/span><\/li>\n<\/ul>\n<h2 id=\"what-compounded-semaglutide-actually-is\"><span style=\"font-weight: 400;\">What compounded semaglutide actually is<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Compounding is the practice of a licensed pharmacy preparing a customized medication for an individual patient \u2014 combining, diluting, or reformulating ingredients rather than dispensing a mass-manufactured, FDA-approved product. It exists for legitimate reasons: a patient allergic to a dye or preservative in <\/span><a href=\"https:\/\/getheally.com\/patients\/ozempic\"><span style=\"font-weight: 400;\">Ozempic<\/span><\/a><span style=\"font-weight: 400;\">, or a dosage form the commercial product doesn&#8217;t offer.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">During 2023 and 2024, semaglutide injection products sat on the FDA&#8217;s official drug shortage list. That status triggered a legal exception allowing pharmacies \u2014 including large 503B outsourcing facilities \u2014 to compound semaglutide in bulk, largely without the individualized justification compounding normally requires. This is the window that produced the wave of $99\u2013$300\/month telehealth semaglutide subscriptions, often bundled with vitamin B12 or B6 &#8220;for energy&#8221;<\/span><\/p>\n<p><span style=\"font-weight: 400;\">That window is closed. The shortage is over, and the rules have reverted \u2014 then tightened further.<\/span><\/p>\n<h2 id=\"the-2025-2026-timeline-in-order\"><span style=\"font-weight: 400;\">The 2025\u20132026 timeline, in order<\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th><b>Date<\/b><\/th>\n<th><b>What happened<\/b><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><span style=\"font-weight: 400;\">December 2024<\/span><\/td>\n<td><span style=\"font-weight: 400;\">FDA resolves the <\/span><b>tirzepatide<\/b><span style=\"font-weight: 400;\"> shortage<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">February 2025<\/span><\/td>\n<td><span style=\"font-weight: 400;\">FDA resolves the <\/span><b>semaglutide<\/b><span style=\"font-weight: 400;\"> shortage<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">April 22, 2025<\/span><\/td>\n<td><span style=\"font-weight: 400;\">503A enforcement discretion for semaglutide compounding ends<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">April 24, 2025<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Federal court denies the Outsourcing Facilities Association&#8217;s injunction request; case proceeds to appeal<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">May 22, 2025<\/span><\/td>\n<td><span style=\"font-weight: 400;\">503B enforcement discretion window closes<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">April 1, 2026<\/span><\/td>\n<td><span style=\"font-weight: 400;\">FDA clarifies the &#8220;essentially a copy&#8221; standard; names semaglutide + B12 as non-qualifying<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">April 30, 2026<\/span><\/td>\n<td><span style=\"font-weight: 400;\">FDA proposes removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list permanently<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">June 29, 2026<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Public comment period on the removal proposal closes<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">September 2026<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Proposal remains pending; 503A patient-specific compounding continues under tightened rules<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">The lawsuit from the compounding industry hasn&#8217;t reversed anything so far \u2014 courts have repeatedly declined to block the FDA&#8217;s shortage-resolution findings, even while the appeal continues.<\/span><\/p>\n<h2 id=\"the-rule-that-actually-matters-essentially-a-copy\"><span style=\"font-weight: 400;\">The rule that actually matters: &#8220;essentially a copy&#8221;<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Federal law restricts compounding pharmacies from producing a drug that is <\/span><b>&#8220;essentially a copy&#8221;<\/b><span style=\"font-weight: 400;\"> of a commercially available FDA-approved product \u2014 unless a specific exemption applies. A compounded product counts as &#8220;essentially a copy&#8221; when it shares the same active ingredient, the same route of administration, and a similar or easily substitutable strength as the approved drug.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Plain compounded semaglutide injection fits that definition cleanly. It&#8217;s chemically the same molecule as Ozempic or Wegovy, injected the same way, at a similar dose. Under ordinary rules, that&#8217;s not allowed to be compounded routinely.<\/span><\/p>\n<p><b><i>The exemption that remains:<\/i><\/b><i><span style=\"font-weight: 400;\"> a prescriber can document that a specific patient has a genuine, individualized clinical reason the FDA-approved product won&#8217;t work for them \u2014 a documented allergy to an inactive ingredient, for example, or a need for a dosage form that doesn&#8217;t exist commercially. This determination has to be made and written down for that one patient. It cannot be a general clinic policy or a template note applied across every patient.<\/span><\/i><\/p>\n<p><span style=\"font-weight: 400;\">The FDA was explicit in its April 2026 clarification that adding vitamin B12 to semaglutide does <\/span><b>not<\/b><span style=\"font-weight: 400;\"> create the kind of difference that qualifies \u2014 because a patient could simply take FDA-approved semaglutide and a B12 supplement separately. This closes the most widely used telehealth workaround of the past two years.<\/span><\/p>\n<p><b>The narrow safe harbor:<\/b><span style=\"font-weight: 400;\"> the FDA has said it does not currently intend to pursue enforcement against a 503A pharmacy that fills <\/span><b>four or fewer prescriptions per calendar month<\/b><span style=\"font-weight: 400;\"> of an essentially-a-copy compounded formulation. This is enforcement discretion, not a statement that the practice is fully compliant \u2014 and it&#8217;s a low-volume allowance, incompatible with a subscription telehealth business filling hundreds of prescriptions a month. If you&#8217;re unsure whether your current dose even falls within a normal range, our guide on <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/how-to-know-when-your-glp-1-dose-is-too-high\"><span style=\"font-weight: 400;\">knowing when your GLP-1 dose is too high<\/span><\/a><span style=\"font-weight: 400;\"> covers the warning signs.<\/span><\/p>\n<h2 id=\"what-the-april-30-2026-proposal-would-change\"><span style=\"font-weight: 400;\">What the April 30, 2026 proposal would change<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Separately from the &#8220;essentially a copy&#8221; clarification, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the <\/span><b>503B bulks list<\/b><span style=\"font-weight: 400;\"> \u2014 the list of substances outsourcing facilities are allowed to compound from bulk ingredient, independent of shortage status. The agency&#8217;s stated reasoning: with FDA-approved products now widely available, including newer high-dose options like Wegovy HD, there&#8217;s no demonstrated clinical need for facilities to compound these molecules from scratch.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">If finalized, this would foreclose large-batch 503B compounding of semaglutide for good \u2014 not just during the current gap, but as a matter of settled policy. The comment period closed June 29, 2026, and a final rule has not yet been issued as of this writing. Prescribers and compounding pharmacies should expect the direction of travel to continue toward restriction, not loosening.<\/span><\/p>\n<h2 id=\"why-the-fda-has-focused-so-heavily-on-enforcement-here\"><span style=\"font-weight: 400;\">Why the FDA has focused so heavily on enforcement here<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">This isn&#8217;t purely a technical rulemaking story. The FDA&#8217;s compounding crackdown followed real, documented harm.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The agency has received <\/span><b>more than 455 adverse event reports<\/b><span style=\"font-weight: 400;\"> connected to compounded semaglutide and <\/span><b>more than 320<\/b><span style=\"font-weight: 400;\"> tied to compounded tirzepatide, some serious enough to require hospitalization. A meaningful share trace back to dosing errors and <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/how-to-treat-a-semaglutide-injection-site-reaction\"><span style=\"font-weight: 400;\">injection site reactions<\/span><\/a><span style=\"font-weight: 400;\"> \u2014 patients self-administering incorrect amounts from multidose vials that lack the built-in dose control of an FDA-approved pen.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A separate concern involves the compound itself. Some compounders have used <\/span><b>semaglutide sodium<\/b><span style=\"font-weight: 400;\"> or <\/span><b>semaglutide acetate<\/b><span style=\"font-weight: 400;\"> \u2014 salt forms that differ chemically from the active ingredient in Ozempic and Wegovy. The FDA has stated there&#8217;s no data confirming these salt forms behave the same way in the body, which means patients using them are, in effect, taking an unstudied variant of the drug.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Neither of these risks is theoretical marketing language \u2014 they&#8217;re the specific findings the FDA has cited to justify tightening enforcement.<\/span><\/p>\n<h2 id=\"if-youre-currently-on-compounded-semaglutide\"><span style=\"font-weight: 400;\">If you&#8217;re currently on compounded semaglutide<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">A few practical points if this applies to you:<\/span><\/p>\n<p><b>Your current supply isn&#8217;t automatically illegal to possess or use<\/b><span style=\"font-weight: 400;\">, but new prescriptions and refills are subject to the tightened rules above. Whether your pharmacy can continue to fill your prescription depends on whether your provider has documented a genuine, patient-specific reason and whether the pharmacy stays within any applicable low-volume threshold.<\/span><\/p>\n<p><b>Ask your provider directly<\/b><span style=\"font-weight: 400;\"> whether your current formulation still qualifies under the current rules, and whether they&#8217;re prepared to document an individualized clinical reason if one genuinely exists \u2014 most people using compounded semaglutide simply for cost reasons will not meet that bar.<\/span><\/p>\n<p><b>If you were using a plain compounded semaglutide injection or a semaglutide-B12 blend for cost reasons alone<\/b><span style=\"font-weight: 400;\">, it&#8217;s worth assuming that pathway is closing and planning your next step now, rather than waiting for a supply disruption to force the decision.<\/span><\/p>\n<h2 id=\"what-to-do-instead\"><span style=\"font-weight: 400;\">What to do instead<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">For most patients who turned to compounded semaglutide because of price, the practical alternatives in September 2026 are meaningfully better than they were two years ago.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/getheally.com\/patients\/semaglutide\"><b>Semaglutide<\/b><\/a><b> self-pay through the manufacturer.<\/b><span style=\"font-weight: 400;\"> NovoCare sells Wegovy vials directly to self-pay patients, and pricing has come down substantially from list price. Combined with the manufacturer savings card for commercially insured patients, many people pay far less out of pocket than the $1,300+\/month list price would suggest.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>The <\/b><a href=\"https:\/\/getheally.com\/patients\/wegovy-pills\"><b>Wegovy pill<\/b><\/a><b>.<\/b><span style=\"font-weight: 400;\"> Oral semaglutide 25 mg, launched January 2026, starts at a self-pay price well below injectable list price and removes the injection entirely for patients who found that a barrier.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Insurance and prior authorization.<\/b><span style=\"font-weight: 400;\"> Coverage for Wegovy has broadened since 2024. If you haven&#8217;t checked your current formulary, it&#8217;s worth a fresh look \u2014 plans that excluded weight-loss GLP-1s two years ago have, in many cases, added coverage since.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Switching to an FDA-approved product with your provider&#8217;s help.<\/b><span style=\"font-weight: 400;\"> If you&#8217;re currently on compounded semaglutide, your Heally provider can review your dose and guide a transition to Wegovy or Ozempic without restarting the entire titration process from zero.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">If tirzepatide is more relevant to your situation, the same shortage-resolution logic applies to it on a similar timeline \u2014 see our guide on <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/how-to-get-tirzepatide-with-insurance\"><span style=\"font-weight: 400;\">getting tirzepatide covered by insurance<\/span><\/a><span style=\"font-weight: 400;\"> for that side of the picture, and our breakdown of <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/how-to-use-a-discount-for-zepbound-from-eli-lilly\"><span style=\"font-weight: 400;\">Zepbound&#8217;s savings card program<\/span><\/a><span style=\"font-weight: 400;\"> for self-pay options.<\/span><\/p>\n<h2 id=\"conclusion\"><span style=\"font-weight: 400;\">Conclusion<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Compounded semaglutide&#8217;s legal footing has shrunk from &#8220;widely available during a documented national shortage&#8221; to &#8220;a narrow exemption for individual patients with a genuine, provider-documented medical reason.&#8221; The mass-market telehealth version of compounded semaglutide \u2014 the $150\/month vial with a B12 add-on \u2014 no longer fits within the rules the FDA has spent 2025 and 2026 clarifying and enforcing, and a pending proposal would close the door further.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">None of this means treatment is out of reach. Brand-name semaglutide is more accessible on price than it was two years ago, between manufacturer self-pay programs, the oral pill option, and expanding insurance coverage. For most patients, that&#8217;s now the more reliable \u2014 and more thoroughly studied \u2014 path.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">If you want to review your current treatment and understand your options under the current rules, <\/span><a href=\"https:\/\/md.getheally.com\/f\/vshop-book_appt?visit_type_first=true&amp;visit_type_ids=3070\"><span style=\"font-weight: 400;\">book a free consultation with Heally<\/span><\/a><span style=\"font-weight: 400;\"> \u2014 licensed providers can walk through what&#8217;s appropriate for your situation and get you started on an FDA-approved option same-day.<\/span><\/p>\n<h2 id=\"faq\"><span style=\"font-weight: 400;\">FAQ<\/span><\/h2>\n<p><b>Is compounded semaglutide still legal in 2026?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In narrow circumstances, yes. A 503A pharmacy can compound it for an individual patient when the prescriber documents a genuine, patient-specific clinical reason the FDA-approved product won&#8217;t work \u2014 not simply for cost. Routine compounding without that documentation, especially at telehealth-subscription scale, falls outside what the FDA currently allows.<\/span><\/p>\n<p><b>Why did compounded semaglutide become illegal?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">It didn&#8217;t become illegal outright \u2014 the legal exception that allowed mass compounding was tied to an official FDA drug shortage, which ended in February 2025. Once the shortage was resolved, compounding reverted to its normal, much narrower rules, which the FDA has since clarified and tightened further through 2026.<\/span><\/p>\n<p><b>Does adding B12 to compounded semaglutide make it legal?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">No. The FDA specifically addressed this in its April 2026 clarification and stated that a semaglutide-plus-B12 combination still counts as &#8220;essentially a copy&#8221; of the approved drug, because a patient could take semaglutide and a B12 supplement separately. This was the most common workaround used by telehealth compounding providers, and it no longer qualifies.<\/span><\/p>\n<p><b>What is the 503B bulks list, and why does it matter?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">It&#8217;s the FDA&#8217;s list of substances outsourcing facilities may compound from bulk ingredient outside of a shortage. Semaglutide isn&#8217;t currently on it. The FDA has proposed formally excluding it (along with tirzepatide and liraglutide), which would permanently close large-scale 503B compounding of these drugs regardless of future shortage status.<\/span><\/p>\n<p><b>Is compounded semaglutide safe?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The FDA has logged more than 455 adverse event reports connected to compounded semaglutide, some requiring hospitalization, largely from dosing errors with multidose vials. Some compounded versions have also used semaglutide salt forms (sodium or acetate) that differ from the approved drug&#8217;s active ingredient and haven&#8217;t been studied for equivalence.<\/span><\/p>\n<p><b>What should I do if I&#8217;m currently using compounded semaglutide?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Talk to your provider about whether your prescription still meets the current documentation requirements, and ask about transitioning to an FDA-approved option like Wegovy, the Wegovy pill, or Ozempic if it doesn&#8217;t. A provider can typically guide this switch without restarting your titration schedule from the very beginning.<\/span><\/p>\n<p><b>Are there cheaper legal alternatives to compounded semaglutide now?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Yes. Manufacturer self-pay pricing for Wegovy has dropped substantially since 2024, the Wegovy pill offers a lower-cost oral option, and insurance coverage for weight-loss GLP-1s has broadened. For many patients, the out-of-pocket gap between compounded and brand-name semaglutide is smaller than it was two years ago.<\/span><\/p>\n<p><b>Is compounded tirzepatide in the same situation?<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Largely yes, on a slightly earlier timeline \u2014 the tirzepatide shortage resolved in December 2024, a few months before semaglutide&#8217;s. The same &#8220;essentially a copy&#8221; standard, the same April 2026 clarification, and the same proposed 503B bulks list removal apply to it as well.<\/span><\/p>\n<p><b>Related reading on Heally:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/getheally.com\/patients\/news\/how-to-get-tirzepatide-with-insurance\"><span style=\"font-weight: 400;\">How to get tirzepatide with insurance: a complete 2026 guide<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/getheally.com\/patients\/news\/how-to-use-a-discount-for-zepbound-from-eli-lilly\"><span style=\"font-weight: 400;\">How to use the Zepbound savings card: a complete 2026 discount guide<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/getheally.com\/patients\/news\/wegovy-pill-dosage-guide\"><span style=\"font-weight: 400;\">Wegovy pill dosage guide: how to take oral semaglutide correctly<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/getheally.com\/patients\/news\/semaglutide-dosing-guidelines\"><span style=\"font-weight: 400;\">Semaglutide dosing guidelines: a complete schedule for 2026<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/getheally.com\/patients\/news\/semaglutide-in-2026-how-many-people-use-it-what-brands-lead-and-where-the-market-is-heading\"><span style=\"font-weight: 400;\">Semaglutide in 2026: usage trends and which brands lead<\/span><\/a><\/li>\n<\/ul>\n<h2 id=\"sources\"><span style=\"font-weight: 400;\">Sources<\/span><\/h2>\n<ol>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Orrick \u2014 <\/span><a href=\"https:\/\/www.orrick.com\/en\/Insights\/2026\/05\/FDA-Moves-to-Shut-the-Door-on-Large-Scale-Compounding-of-GLP1-Drugs\"><span style=\"font-weight: 400;\">FDA moves to shut the door on large-scale compounding of GLP-1 drugs<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Pharmacy Times \u2014 <\/span><a href=\"https:\/\/www.pharmacytimes.com\/view\/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s\"><span style=\"font-weight: 400;\">FDA moves to permanently close the door on compounded GLP-1s<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Foley &amp; Lardner \u2014 <\/span><a href=\"https:\/\/www.foley.com\/insights\/publications\/2026\/04\/fda-clarifies-policies-for-pharmacy-compounders-of-glp-1-products\/\"><span style=\"font-weight: 400;\">FDA clarifies policies for pharmacy compounders of GLP-1 products<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">National Law Review \u2014 <\/span><a href=\"https:\/\/natlawreview.com\/article\/not-joking-around-fda-offers-additional-clarification-compounded-glp-1-policy-april\"><span style=\"font-weight: 400;\">FDA offers additional clarification on compounded GLP-1 policy<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">National Association of Boards of Pharmacy \u2014 <\/span><a href=\"https:\/\/nabp.pharmacy\/news\/blog\/regulatory_news\/fda-clarifies-policies-compounding-drugs-sections-503a-and-503b\/\"><span style=\"font-weight: 400;\">FDA clarifies policies for compounding drugs under Sections 503A and 503B<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">FDA \u2014 <\/span><a href=\"https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/compounding-and-fda-questions-and-answers\"><span style=\"font-weight: 400;\">Compounding and the FDA: questions and answers<\/span><\/a><\/li>\n<\/ol>\n<p><i><span style=\"font-weight: 400;\">Medical disclaimer: This article summarizes public regulatory developments as understood in September 2026 and is not legal advice. Compounding rules are subject to further change, including a pending FDA rulemaking. This article does not replace medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any prescription medication.<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"Compounded semaglutide is not the workaround it was in 2023 and 2024. The FDA shortage that made mass&hellip;\n","protected":false},"author":10,"featured_media":29141,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1794],"tags":[1962,2418,2419,1793],"class_list":{"0":"post-29155","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-weight-loss","8":"tag-compounded-semaglutide","9":"tag-compounding","10":"tag-medication-types","11":"tag-semaglutide"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Compounded semaglutide in 2026 - Heally<\/title>\n<meta name=\"description\" content=\"Compound semaglutide is no longer allowed for use. Learn why FDA directs patients to Wegovy and how Heally helps with access and savings\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Compounded semaglutide in 2026 - Heally\" \/>\n<meta property=\"og:description\" content=\"Compound semaglutide is no longer allowed for use. Learn why FDA directs patients to Wegovy and how Heally helps with access and savings\" \/>\n<meta property=\"og:url\" content=\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide\" \/>\n<meta property=\"og:site_name\" content=\"Heally\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/getheally.com\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-21T17:51:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-22T11:27:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/07\/Semaglutide_Injection_Bottle.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Ben Krasne MD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ben Krasne MD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#article\",\"isPartOf\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide\"},\"author\":{\"name\":\"Ben Krasne MD\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#\/schema\/person\/133ab039fcce2b4f2ef87ae214ab9211\"},\"headline\":\"Compounded semaglutide in 2026: what&#8217;s actually still legal\",\"datePublished\":\"2026-09-21T17:51:00+00:00\",\"dateModified\":\"2026-09-22T11:27:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide\"},\"wordCount\":2377,\"publisher\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#primaryimage\"},\"thumbnailUrl\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/07\/Semaglutide_Injection_Bottle.png\",\"keywords\":[\"compounded semaglutide\",\"Compounding\",\"Medication Types\",\"semaglutide\"],\"articleSection\":[\"Weight Loss\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide\",\"url\":\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide\",\"name\":\"Compounded semaglutide in 2026 - Heally\",\"isPartOf\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#primaryimage\"},\"image\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#primaryimage\"},\"thumbnailUrl\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/07\/Semaglutide_Injection_Bottle.png\",\"datePublished\":\"2026-09-21T17:51:00+00:00\",\"dateModified\":\"2026-09-22T11:27:16+00:00\",\"description\":\"Compound semaglutide is no longer allowed for use. Learn why FDA directs patients to Wegovy and how Heally helps with access and savings\",\"breadcrumb\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#primaryimage\",\"url\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/07\/Semaglutide_Injection_Bottle.png\",\"contentUrl\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/07\/Semaglutide_Injection_Bottle.png\",\"width\":1080,\"height\":1080,\"caption\":\"compounded semaglutide form heally\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/getheally.com\/patients\/news\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Compounded semaglutide in 2026: what&#8217;s actually still legal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#website\",\"url\":\"https:\/\/getheally.com\/patients\/news\/\",\"name\":\"Heally\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/getheally.com\/patients\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#organization\",\"name\":\"Heally\",\"url\":\"https:\/\/getheally.com\/patients\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2019\/05\/heallybl.png\",\"contentUrl\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2019\/05\/heallybl.png\",\"width\":152,\"height\":52,\"caption\":\"Heally\"},\"image\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/getheally.com\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#\/schema\/person\/133ab039fcce2b4f2ef87ae214ab9211\",\"name\":\"Ben Krasne MD\",\"description\":\"Dr. Benjamin Krasne is a board-certified anesthesiologist. After attending the University of Florida, Dr. Ben matriculated to the University of Miami Miller School of Medicine. Dr. Krasne completed his residency at Jackson Memorial Hospital in 2017. Since graduating residency Dr. Krasne has worked throughout the United States as a traveling anesthesiologist while providing remote driven out-patient clinical services as well.\",\"sameAs\":[\"https:\/\/www.parkwayrestorativedentistry.com\/dr-benjamin-krasne\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Compounded semaglutide in 2026 - Heally","description":"Compound semaglutide is no longer allowed for use. Learn why FDA directs patients to Wegovy and how Heally helps with access and savings","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide","og_locale":"en_US","og_type":"article","og_title":"Compounded semaglutide in 2026 - Heally","og_description":"Compound semaglutide is no longer allowed for use. Learn why FDA directs patients to Wegovy and how Heally helps with access and savings","og_url":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide","og_site_name":"Heally","article_publisher":"https:\/\/getheally.com","article_published_time":"2026-09-21T17:51:00+00:00","article_modified_time":"2026-09-22T11:27:16+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/07\/Semaglutide_Injection_Bottle.png","type":"image\/png"}],"author":"Ben Krasne MD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ben Krasne MD","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#article","isPartOf":{"@id":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide"},"author":{"name":"Ben Krasne MD","@id":"https:\/\/getheally.com\/patients\/news\/#\/schema\/person\/133ab039fcce2b4f2ef87ae214ab9211"},"headline":"Compounded semaglutide in 2026: what&#8217;s actually still legal","datePublished":"2026-09-21T17:51:00+00:00","dateModified":"2026-09-22T11:27:16+00:00","mainEntityOfPage":{"@id":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide"},"wordCount":2377,"publisher":{"@id":"https:\/\/getheally.com\/patients\/news\/#organization"},"image":{"@id":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#primaryimage"},"thumbnailUrl":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/07\/Semaglutide_Injection_Bottle.png","keywords":["compounded semaglutide","Compounding","Medication Types","semaglutide"],"articleSection":["Weight Loss"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide","url":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide","name":"Compounded semaglutide in 2026 - Heally","isPartOf":{"@id":"https:\/\/getheally.com\/patients\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#primaryimage"},"image":{"@id":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#primaryimage"},"thumbnailUrl":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/07\/Semaglutide_Injection_Bottle.png","datePublished":"2026-09-21T17:51:00+00:00","dateModified":"2026-09-22T11:27:16+00:00","description":"Compound semaglutide is no longer allowed for use. Learn why FDA directs patients to Wegovy and how Heally helps with access and savings","breadcrumb":{"@id":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/getheally.com\/patients\/news\/compounded-semaglutide"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#primaryimage","url":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/07\/Semaglutide_Injection_Bottle.png","contentUrl":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/07\/Semaglutide_Injection_Bottle.png","width":1080,"height":1080,"caption":"compounded semaglutide form heally"},{"@type":"BreadcrumbList","@id":"https:\/\/getheally.com\/patients\/news\/compounded-semaglutide#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/getheally.com\/patients\/news"},{"@type":"ListItem","position":2,"name":"Compounded semaglutide in 2026: what&#8217;s actually still legal"}]},{"@type":"WebSite","@id":"https:\/\/getheally.com\/patients\/news\/#website","url":"https:\/\/getheally.com\/patients\/news\/","name":"Heally","description":"","publisher":{"@id":"https:\/\/getheally.com\/patients\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/getheally.com\/patients\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/getheally.com\/patients\/news\/#organization","name":"Heally","url":"https:\/\/getheally.com\/patients\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/getheally.com\/patients\/news\/#\/schema\/logo\/image\/","url":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2019\/05\/heallybl.png","contentUrl":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2019\/05\/heallybl.png","width":152,"height":52,"caption":"Heally"},"image":{"@id":"https:\/\/getheally.com\/patients\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/getheally.com"]},{"@type":"Person","@id":"https:\/\/getheally.com\/patients\/news\/#\/schema\/person\/133ab039fcce2b4f2ef87ae214ab9211","name":"Ben Krasne MD","description":"Dr. Benjamin Krasne is a board-certified anesthesiologist. After attending the University of Florida, Dr. Ben matriculated to the University of Miami Miller School of Medicine. Dr. Krasne completed his residency at Jackson Memorial Hospital in 2017. Since graduating residency Dr. Krasne has worked throughout the United States as a traveling anesthesiologist while providing remote driven out-patient clinical services as well.","sameAs":["https:\/\/www.parkwayrestorativedentistry.com\/dr-benjamin-krasne"]}]}},"_links":{"self":[{"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/posts\/29155","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/comments?post=29155"}],"version-history":[{"count":10,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/posts\/29155\/revisions"}],"predecessor-version":[{"id":37880,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/posts\/29155\/revisions\/37880"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/media\/29141"}],"wp:attachment":[{"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/media?parent=29155"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/categories?post=29155"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/tags?post=29155"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}